GSK starts Phase III RSV candidate vaccine programme for older adults

- High levels of RSVPreF3 IgG antibodies (geometric mean antibody concentrations were 12.4 fold-higher) and RSV-A neutralising antibodies (geometric mean antibody titers were 9.5 fold-higher) were induced.
- Before vaccination, deficiency of RSVPreF3-specific T-cells (hypothesised to help promote viral clearance) was observed in older adults compared to younger adults. After vaccination, a robust RSVPreF3 CD4+ T-cells response in older adults had been boosted to reach a similar range than the one observed in younger adults.